Which has stronger valuation and earnings, PPBT or JSPR?

Purple Biotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Purple Biotech N/A N/A -$26.39M -$18.84 N/A Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A

Is PPBT or JSPR more profitable?

Purple Biotech's return on equity of -123.63% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -123.63% -98.72% Jasper Therapeutics N/A -613.51% -162.52%

Which has higher valuation and earnings, PPBT or INAB?

IN8bio is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Purple Biotech N/A N/A -$26.39M -$18.84 N/A IN8bio N/A N/A -$19.44M -$2.61 N/A

Is PPBT or INAB more profitable?

IN8bio's return on equity of -96.39% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -123.63% -98.72% IN8bio N/A -96.39% -80.18%

Is LEXX or PPBT more profitable?

Purple Biotech's return on equity of -123.63% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -206.02% -162.53% Purple Biotech N/A -123.63% -98.72%

Do analysts recommend BLRX or PPBT?

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 913.51%. Given Purple Biotech's higher possible upside, analysts clearly believe Purple Biotech is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BLRX or PPBT more profitable?

Purple Biotech has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% Purple Biotech N/A -123.63% -98.72%

Which has higher earnings and valuation, PPBT or COCP?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Purple Biotech N/A N/A -$26.39M -$18.84 N/A Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A

Is PPBT or COCP more profitable?

Purple Biotech's return on equity of -123.63% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -123.63% -98.72% Cocrystal Pharma N/A -150.61% -97.86%

Purple Biotech (PPBT) Competitors

$2.96 -0.03 (-1.00%)

Closing price 06/10/2026 04:00 PM Eastern

Extended Trading

$2.84 -0.12 (-4.05%)

As of 04:04 AM Eastern

Compare

PPBT vs. JSPR, INAB, LEXX, BLRX, and COCP

Should you buy Purple Biotech stock or one of its competitors? MarketBeat compares Purple Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Purple Biotech include Jasper Therapeutics (JSPR), IN8bio (INAB), Lexaria Bioscience (LEXX), BioLineRx (BLRX), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceutical products" industry.

How does Purple Biotech compare to Jasper Therapeutics?

Purple Biotech (NASDAQ:PPBT) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Purple Biotech currently has a consensus target price of $30.00, indicating a potential upside of 913.51%. Jasper Therapeutics has a consensus target price of $13.14, indicating a potential upside of 2,730.68%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Purple Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Purple Biotech and Purple Biotech both had 2 articles in the media. Jasper Therapeutics' average media sentiment score of 0.63 beat Purple Biotech's score of 0.44 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Purple Biotech	Neutral
Jasper Therapeutics	Positive

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Purple Biotech has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3, indicating that its share price is 200% more volatile than the broader market.

Purple Biotech's return on equity of -123.63% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Jasper Therapeutics	N/A	-613.51%	-162.52%

Purple Biotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

Summary

Jasper Therapeutics beats Purple Biotech on 9 of the 12 factors compared between the two stocks.

How does Purple Biotech compare to IN8bio?

Purple Biotech (NASDAQ:PPBT) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

IN8bio's return on equity of -96.39% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
IN8bio	N/A	-96.39%	-80.18%

Purple Biotech has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, IN8bio has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Purple Biotech presently has a consensus target price of $30.00, indicating a potential upside of 913.51%. IN8bio has a consensus target price of $4.00, indicating a potential upside of 185.71%. Given Purple Biotech's higher probable upside, analysts clearly believe Purple Biotech is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 3.0% of Purple Biotech shares are held by company insiders. Comparatively, 14.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IN8bio is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

In the previous week, Purple Biotech and Purple Biotech both had 2 articles in the media. IN8bio's average media sentiment score of 0.77 beat Purple Biotech's score of 0.44 indicating that IN8bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Purple Biotech	Neutral
IN8bio	Positive

Summary

IN8bio beats Purple Biotech on 7 of the 10 factors compared between the two stocks.

How does Purple Biotech compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Lexaria Bioscience has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Lexaria Bioscience presently has a consensus target price of $1.50, indicating a potential upside of 128.66%. Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 913.51%. Given Purple Biotech's higher possible upside, analysts clearly believe Purple Biotech is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Purple Biotech had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Lexaria Bioscience. Purple Biotech's average media sentiment score of 0.44 beat Lexaria Bioscience's score of 0.37 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Lexaria Bioscience	Neutral
Purple Biotech	Neutral

Lexaria Bioscience has higher revenue and earnings than Purple Biotech. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	22.90	-$11.90M	-$0.47	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

Purple Biotech's return on equity of -123.63% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-206.02%	-162.53%
Purple Biotech	N/A	-123.63%	-98.72%

Summary

Purple Biotech beats Lexaria Bioscience on 7 of the 12 factors compared between the two stocks.

How does Purple Biotech compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

BioLineRx has higher revenue and earnings than Purple Biotech. BioLineRx is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	12.15	-$1.17M	-$1.92	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

Purple Biotech has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Purple Biotech	N/A	-123.63%	-98.72%

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 913.51%. Given Purple Biotech's higher possible upside, analysts clearly believe Purple Biotech is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioLineRx has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

In the previous week, BioLineRx and BioLineRx both had 2 articles in the media. BioLineRx's average media sentiment score of 1.12 beat Purple Biotech's score of 0.44 indicating that BioLineRx is being referred to more favorably in the media.

Company	Overall Sentiment
BioLineRx	Positive
Purple Biotech	Neutral

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BioLineRx beats Purple Biotech on 7 of the 12 factors compared between the two stocks.

How does Purple Biotech compare to Cocrystal Pharma?

Purple Biotech (NASDAQ:PPBT) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Purple Biotech's return on equity of -123.63% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Cocrystal Pharma	N/A	-150.61%	-97.86%

Purple Biotech has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

In the previous week, Purple Biotech had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Cocrystal Pharma. Purple Biotech's average media sentiment score of 0.44 beat Cocrystal Pharma's score of 0.29 indicating that Purple Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Purple Biotech	Neutral
Cocrystal Pharma	Neutral

Purple Biotech currently has a consensus target price of $30.00, suggesting a potential upside of 913.51%. Cocrystal Pharma has a consensus target price of $6.00, suggesting a potential upside of 500.00%. Given Purple Biotech's higher probable upside, equities research analysts plainly believe Purple Biotech is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Purple Biotech beats Cocrystal Pharma on 6 of the 11 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPBT vs. The Competition

Export

Metric	Purple Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.84M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.32%	2.67%	5.61%
P/E Ratio	-0.16	18.83	24.41	23.63
Price / Sales	N/A	294.36	502.20	102.41
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	0.39	8.00	10.30	6.70
Net Income	-$26.39M	$23.89M	$3.56B	$337.26M
7 Day Performance	-4.21%	-5.43%	-2.93%	-2.43%
1 Month Performance	-27.09%	-4.18%	-0.36%	0.19%
1 Year Performance	-88.44%	36.70%	20.08%	23.16%

Purple Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPBT Purple Biotech	3.2299 of 5 stars	$2.96 -1.0%	$30.00 +913.5%	-88.8%	$3.84M	N/A	N/A	20	Short Interest Increase
JSPR Jasper Therapeutics	3.2243 of 5 stars	$0.55 +3.2%	$13.14 +2,284.0%	-92.0%	$15.44M	N/A	N/A	20	Gap Up High Trading Volume
INAB IN8bio	3.7837 of 5 stars	$1.56 -9.8%	$4.00 +156.4%	-51.4%	$15.37M	N/A	N/A	20	Short Interest Decrease Gap Down
LEXX Lexaria Bioscience	2.1791 of 5 stars	$0.60 -2.5%	$1.50 +149.6%	-37.5%	$14.90M	$368K	N/A	7	Positive News Gap Down
BLRX BioLineRx	0.9659 of 5 stars	$3.39 -2.6%	N/A	-43.6%	$14.81M	$1.18M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPBT) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Purple Biotech (PPBT) Competitors

PPBT vs. JSPR, INAB, LEXX, BLRX, and COCP

How does Purple Biotech compare to Jasper Therapeutics?

Summary

How does Purple Biotech compare to IN8bio?

Summary

How does Purple Biotech compare to Lexaria Bioscience?

Summary

How does Purple Biotech compare to BioLineRx?

Summary

How does Purple Biotech compare to Cocrystal Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Purple Biotech (PPBT) Competitors

PPBT vs. JSPR, INAB, LEXX, BLRX, and COCP

How does Purple Biotech compare to Jasper Therapeutics?

Do analysts prefer PPBT or JSPR?

Does the media refer more to PPBT or JSPR?

Do insiders and institutionals have more ownership in PPBT or JSPR?

Which has more volatility and risk, PPBT or JSPR?

Is PPBT or JSPR more profitable?

Which has stronger valuation and earnings, PPBT or JSPR?

Summary

How does Purple Biotech compare to IN8bio?

Is PPBT or INAB more profitable?

Which has more risk & volatility, PPBT or INAB?

Do analysts rate PPBT or INAB?

Do institutionals and insiders have more ownership in PPBT or INAB?

Which has higher valuation and earnings, PPBT or INAB?

Does the media refer more to PPBT or INAB?

Summary

How does Purple Biotech compare to Lexaria Bioscience?

Which has more volatility and risk, LEXX or PPBT?

Do analysts recommend LEXX or PPBT?

Do insiders & institutionals have more ownership in LEXX or PPBT?

Does the media refer more to LEXX or PPBT?

Which has stronger earnings and valuation, LEXX or PPBT?

Is LEXX or PPBT more profitable?

Summary

How does Purple Biotech compare to BioLineRx?

Which has higher valuation & earnings, BLRX or PPBT?

Is BLRX or PPBT more profitable?

Do analysts recommend BLRX or PPBT?

Which has more volatility & risk, BLRX or PPBT?

Does the media prefer BLRX or PPBT?

Do insiders and institutionals hold more shares of BLRX or PPBT?

Summary

How does Purple Biotech compare to Cocrystal Pharma?

Is PPBT or COCP more profitable?

Which has more risk and volatility, PPBT or COCP?

Do institutionals and insiders believe in PPBT or COCP?

Which has higher earnings and valuation, PPBT or COCP?

Does the media favor PPBT or COCP?

Do analysts prefer PPBT or COCP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools